| Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis–Targeted Therapy Given in the Metastatic Castration-Sensitive Versus … N Sayegh, N Tripathi, RH Nussenzveig, VM Thomas, C Tandar, D Goel, ... European Urology Focus 9 (1), 106-109, 2023 | 3 | 2023 |
| Survival outcomes and characterization of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT … N Sayegh, N Tripathi, B Chigarira, Y Jo, TR McFarland, A Kessel, ... Journal of Clinical Oncology 40 (6_suppl), 123-123, 2022 | 2 | 2022 |
| Transcriptomic profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (DN-mCSPC) versus those with mCSPC that have relapsed from prior … N Sayegh, B Chigarira, EJ Hernandez, TR McFarland, H Li, KK Sahu, ... Journal of Clinical Oncology 40 (16_suppl), 5080-5080, 2022 | 1 | 2022 |
| Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing … U Swami, B Chigarira, N Sayegh, TR McFarland, N Tripathi, ... Journal of Clinical Oncology 40 (6_suppl), 133-133, 2022 | 1 | 2022 |
| Tumor genomic landscape in younger compared to older patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC). N Tripathi, H Li, Y Jo, N Sayegh, C Tandar, R Nussenzveig, B Haaland, ... Journal of Clinical Oncology 40 (6_suppl), 373-373, 2022 | 1 | 2022 |
| Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report TR McFarland, CE Tandar, N Agarwal, U Swami Cancer Treatment and Research Communications 29, 100480, 2021 | 1 | 2021 |
| Social Media and Artificial Intelligence–Understanding Medical Misinformation Through Snapchat’s New AI Chatbot CE Tandar, SS Bajaj, FC Stanford Mayo Clinic Proceedings: Digital Health, 2024 | | 2024 |
| Natural course of metastatic castration‐resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone‐sensitive setting G Gebrael, C Hage Chehade, N Sayegh, N Tripathi, B Chigarira, D Goel, ... The Prostate, 2024 | | 2024 |
| Tumor genomic and transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus do not achieve an optimal PSA response … VM Thomas, B Chigarira, G Gebrael, C Chehade, A Narang, N Sayegh, ... Cancer Research 84 (6_Supplement), 1136-1136, 2024 | | 2024 |
| Genomic biomarkers of survival in patients (pts) with metastatic castrate-sensitive prostate cancer (mCSPC) undergoing androgen deprivation therapy (ADT) intensification (ADTi) A Narang, G Gebrael, CH Chehade, N Sayegh, Y Jo, B Chigarira, ... Cancer Research 84 (6_Supplement), 2560-2560, 2024 | | 2024 |
| Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy (iADT) with relugolix. P Campbell, G Gebrael, A Narang, C Hage Chehade, V Mathew Thomas, ... Journal of Clinical Oncology 42 (4_suppl), 70-70, 2024 | | 2024 |
| Disease characteristics, survival outcomes, and tumor molecular landscape in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) harboring CDK12 … C Hage Chehade, G Gebrael, A Srivastava, N Tripathi, N Sayegh, ... Journal of Clinical Oncology 42 (4_suppl), 189-189, 2024 | | 2024 |
| Differences in the Tumor Transcriptomic Profile of Patients with Advanced Prostate Cancer with and without Diabetes Mellitus GMG Fortuna, N Tripathi, H Li, B Chigarira, SA Kumar, K JongTaek, ... International Journal of Cancer Care and Delivery 3 (Supplement 2), 2023 | | 2023 |
| Differential Tumor Gene Expression Profiling of Obese and Non-Obese Patients (pts) with Prostatic Adenocarcinoma (PC) VM Thomas, B Chigarira, G Gebrael, N Sayegh, N Tripathi, ... International Journal of Cancer Care and Delivery 3 (Supplement 2), 2023 | | 2023 |
| Correlation of tumor gene expression profile and gleason score (GS) in patients (pts) with metastatic prostate cancer G Gebrael, N Sayegh, N Tripathi, B Chigarira, Y Jo, VM Thomas, ... International Journal of Cancer Care and Delivery 3 (Supplement 2), 2023 | | 2023 |
| Recruitment to retention-Addressing the needs and driving improvement within the rural physician pipeline CE Tandar, SS Bajaj, FC Stanford The American journal of the medical sciences, S0002-9629 (23) 01364-2, 2023 | | 2023 |
| Differential tumor gene expression profiling of obese and non-obese patients (pts) with prostatic adenocarcinoma (PC). V Mathew Thomas, B Chigarira, G Gebrael, N Sayegh, N Tripathi, ... Journal of Clinical Oncology 41 (16_suppl), 5075-5075, 2023 | | 2023 |
| Tumor transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus who do not achieve an optimal PSA response to … V Mathew Thomas, N Sayegh, B Chigarira, G Gebrael, Y Jo, N Tripathi, ... Journal of Clinical Oncology 41 (6_suppl), 234-234, 2023 | | 2023 |
| Association of obesity with tumor differential gene expression and gene set enrichment pathways in advanced prostate adenocarcinoma (PCa). V Mathew Thomas, B Chigarira, G Gebrael, N Sayegh, N Tripathi, Y Jo, ... Journal of Clinical Oncology 41 (6_suppl), 231-231, 2023 | | 2023 |
| Differences in the tumor transcriptomic profile of patients (pts) with advanced prostate cancer (PCa) with and without diabetes mellitus (DM). N Tripathi, H Li, B Chigarira, SA Kumar, K JongTaek, N Sayegh, ... Journal of Clinical Oncology 41 (6_suppl), 244-244, 2023 | | 2023 |
